Alnylam's Amvuttra data support efficacy across ATTR patient groups
Source Summary
Alnylam Pharmaceuticals released clinical data demonstrating that Amvuttra shows efficacy across multiple patient groups with ATTR amyloidosis. The company also advanced its hypertension drug candidate. The data support the broad applicability of Amvuttra in treating different ATTR patient populations.
Why it matters
Positive clinical data across multiple ATTR patient groups strengthens Amvuttra's market position and supports its potential for broader patient adoption.
